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Abstract: Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of
antiresorptive and antiangiogenic agents, and it is also a potentially painful and debilitating condition.
To date, no specific studies have prospectively evaluated the efficacy of its treatment and no robust
standard of care has been established. Therefore, a systematic review (2007–2020) with a pooled
analysis was performed in order to compare MRONJ surgical techniques (conservative or aggressive)
versus combined surgical procedures (surgery plus a non-invasive procedure), where 1137 patients
were included in the pooled analysis. A statistically significant difference in the 6-month improvement
rate, comparing combined conservative surgery versus only aggressive (91% versus 72%, p = 0.05),
was observed. No significant difference regarding any group with respect to the 6-month total
resolution rate (82% versus 72%) was demonstrated. Of note, conservative surgery combined with
various, adjuvant, non-invasive procedures (ozone, LLLT or blood component + Nd:YAG) was found
to achieve partial or full healing in all stages, with improved results and the amelioration of many
variables. In conclusion, specific adjuvant treatments associated with minimally conservative surgery
can be considered effective and safe in the treatment of MRONJ, although well-controlled studies are
a requisite in arriving at definitive statements
Keywords: ONJ; osteonecrosis; treatment; therapy; surgery; staging
1. Introduction
Medication-related osteonecrosis of the jaw (MRONJ) is a drug-related adverse re-
action, characterized by the progressive destruction of bone in the mandible or maxilla.
It occurs in subjects currently or previously exposed to treatment with drugs in which
an increased risk of osteonecrosis can be observed, in the absence of previous radiation
treatment or metastatic disease to the jaw [1]. MRONJ is a severe, emerging orofacial
disease, and thousands of cases have been reported since 2003 [2]. It can be associated
with two categories of drugs: (1) anti-resorptive agents (e.g., bisphosphonates/BP and
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denosumab), used for the treatment of diseases involving the skeletal system in patients
with bone metastases, hematological (e.g., myeloma) or osteometabolic disease (e.g., pri-
mary or secondary osteoporosis, Paget’s disease), and (2) other non-antiresorptive drugs
(antiangiogenic agents, mTOR inhibitors, monoclonal antibodies, etc.) for the treatment of
different types of cancer. Recent data indicate that the incidence of MRONJ varies between
0 and 12.222 per 100,000 patient-years for cancer patients being treated with intravenous
bisphosphonates. The incidence varies from 1.04 to 69 per 100,000 patient-years for os-
teometabolic patients when taking oral bisphosphonates, whereas this value is 30.2 per
100,000 patient-years [3,4] for patients taking denosumab. This variability depends mainly
on several local and systemic risk factors. Regarding the latter, the most recognized are:
primary disease in patients (cancer versus osteoporosis), a specific drug regimen, potency
of the ONJ-related drug and the cumulative dose of BPs [1,5–7]. After a diagnosis of
MRONJ, and whilst adhering to clinical and radiological protocols, the stage (i.e., severity
and extent of the disease) must be defined in order to provide the patient with effective
therapeutic management [7].
Whilst different treatments (therapeutic or palliative) have been described for MRONJ
management, it is still a matter of controversy in the oral and maxillofacial communities
that a gold standard has not yet been defined. In brief, this standard would involve the
three main categories of MRONJ: (a) non-invasive procedures (ranging from pharmaco-
logical to laser treatment) [8,9], (b) invasive techniques (i.e., conservative or aggressive
surgical approaches) [10] and (c) a combination of (a) and (b) (i.e., surgery plus one of the
aforementioned non-invasive procedures) [11]. Non-invasive procedures include: medical
treatment, intraoral vacuum-assisted treatment [12], the use of pentoxifylline (associated
or not with tocopherol [13,14]), Er:YAG laser ablation, and Nd:YAG/diode laser biostimu-
lation [15–17] and teriparatide [18–21]. Only partial and delayed healing has been reported
with non-invasive techniques, to the exclusion of low-level laser treatment (LLLT) and, in
certain cases, teriparatide. Furthermore, there is a paucity of high-impact studies in the
literature, which would demonstrate effective positive outcomes [22].
Surgical treatments comprise: (i) conservative approaches, such as bone debridement,
and sequestrectomy, and (ii) invasive, more aggressive procedures, such as re-sectioning the
affected bone and jawbone reconstruction, where indicated. Several studies have yielded
very positive results for surgical treatment in MRONJ treatment, especially if performed in
the early stages of the disease [23–26].
Many in the field consider that the term ‘treatment’ is often used inappropriately,
in that it is not possible for the disease to heal completely or for the majority of MRONJ
patients to arrive at a state of remission. Thus, and as documented in the MRONJ literature,
treatment goals are mainly concerned with managing pain, controlling for any infection of
the soft and hard tissues and reducing the progression or occurrence of bone necrosis [11].
Over and above every consideration, the authors of this paper hold that maximizing a
patient’s quality of life has to be a key feature of every protocol requiring MRONJ treatment.
The aim of this systematic review with a pooled analysis is to examine and compare
the main categories of MRONJ treatment: surgical techniques (conservative or aggressive)
versus combined procedures (surgery plus non-invasive procedures), by focusing on their
therapeutic effectiveness. The recommendations outlined by the Prisma-P 2015 checklist
systematic review protocol were followed in order to formulate the methodology for this
systematic review.
2. Materials and Methods
The present study followed the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA) and the Meta-analysis of Observational Studies in Epi-
demiology (MOOSE) guidelines. The PICO search strategy considered: patients who
underwent conservative or aggressive surgery with or without combined procedures
(auxiliary treatments). Selected outcomes were a 6-month complete resolution rate, or a
6-month improvement rate in terms of a transition from a higher to a lower stage.
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2.1. Eligibility Criteria
In order to be included in the systematic review outlined in this paper, studies had
to include results from: prospective, non-randomized and randomized clinical trials,
retrospective cohort studies and case series (n ≥ 10), which investigated the role of surgical
(conservative or aggressive) techniques with or without combined procedures (surgery
plus a non-invasive one) and with a follow-up ≥ 6 months. Studies were excluded if
they constituted a Commentary, Review, Editorial or Protocol. Case series (n < 10) or case
reports were excluded from the pooled analysis, and the studies were limited to research
regarding human beings.
2.2. Information Sources and Search Strategy
A systematic, electronic search through different biomedical databases (e.g., PubMed,
Ovide/MEDLINE, Web of Knowledge, Embase and the Cochrane Library) was performed
by two authors (A.G. and F.C.) in the period from January 2007 to December 2020, and it
was restricted to abstracts in English. The MeSH searched terms are included in Table 1.
Table 1. MeSH terms.
“Osteonecrosis”[Mesh] AND “Jaw Diseases”[Mesh]
n AND (“Conservative Treatment”[Mesh]
# OR “Drug Therapy”[Mesh]
# OR “Therapeutics”[Mesh]
# OR “therapy” [Subheading]
# OR “Surgical Procedures, Operative”[Mesh]
# OR “drug therapy” [Subheading])
n AND “Ozone”[Mesh]
n AND “Teriparatide”[Mesh]
n AND (“Laser Therapy”[Mesh]
# OR “Low-Level Light Therapy”[Mesh])
n AND “Pentoxifylline”[Mesh]
n AND “Hyperbaric Oxygenation”[Mesh]
n AND “Tocopherols”[Mesh]
n AND “Platelet-Rich Plasma”[Mesh]
n AND “Bone Morphogenetic Proteins”[Mesh]
n AND “Parathyroid Hormone”[Mesh])
Furthermore, other data sources (from international meetings and indexed dentistry
journals such as Journal of Dentistry, Journal of Oral Maxillofacial Surgery, Journal of
Dental Research) were scanned as a source of grey literature.
2.2.1. Study Selection
Screening and eligibility were assessed independently by two reviewers (F.C. and
O.D.F.), who were in agreement regarding the results. The Titles of papers and Abstracts
were initially screened for relevance and possible eligible results, and thereafter full texts
were retrieved. Finally, the reviewers combined their results to create a corpus of selected
papers to assess for final eligibility. According to the aim of this review, the resulting papers
were allocated to four experimental categories: (1) conservative surgery, (2) aggressive
surgery, (3) a conservative plus non-invasive procedure and (4) aggressive surgery plus
non-invasive protocols. Tables 2 and 3 summarize the eligible studies.
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Table 2. Summary of the characteristics and the results of the studies concerning MRONJ surgical therapies.








Removal of the exposed necrotic bone and primary
wound closure
Complete healing and
new bone formation in
the surgical site
26 months




Surgical removal of whole necrotic bone, extraction of
all compromised teeth Complete healing 12 months
De Souza Faloni




Conservative debridement of the necrotic bone and of
part of the surrounding healthy bone, as a margin of
safety






Conservative surgical debridement Complete healing Average of 4months




Sequestrectomy and/or ostectomy and/or osteoplasty
until bone marrow bleeding
60% patients completely
healed 6 months




Patient underwent conventional surgery, and the bone
defects were filled with absorbable collagen plugs.
Complete healing and
new bone formation in
the surgical site
3 months




The affected bony tissues were curetted from the
surface of the bone using bone curettes and round
tungsten carbide burs. The necrotic bone was








Conservative surgical treatments consisted of
sequestrectomy of necrotic bone, superficial
debridement/curettage, or corticotomy/surgical
removal of alveolar and/or cortical bone
53% patients completely
healed 9 months
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Table 2. Cont.
Treatment Study Study Type Pts Intervention Outcome Follow-Up




Conservative surgical treatments included
sequestrectomies, superficial debridement/curettage
and corticotomies/surgical removal of surrounding










Surgical debridement of the necrotic bone 33% patients completelyhealed 24 months


















Minor surgical debridement was performed after
irrigation, in which the necrotic bone fragments were
removed






Complete electrical or manual removal of the
osteonecrosis until points of bleeding from the bone
can be macroscopically detected.
88.8% patients
completely healed 6 months (72%)







Local debridement was comprised of all surgical
interventions, such as sequestrectomy, soft tissue
debridement and curettage, that did not require bone











The extensive necrotic bone area was surgically
removed, resulting in oral sinus communication. A
buccal fat pad was used to cover the defect
Complete healing 3 months




Sequestrectomy and bone debridement. The overlying
mucosa was sutured over the defect with
reconstruction with buccal fat pad.
Complete healing Average of 12months




Removal of the necrotic bone and primary closure of
the oroantral communication using a buccal fat pad
flap.
Complete healing Average of 12months
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Table 2. Cont.
Treatment Study Study Type Pts Intervention Outcome Follow-Up







Removal of all necrotic bone until bleeding was
obtaining at the bony margins, conscious smoothing of
all sharp bone edges and primary closure of the
wound.
87% patients








One group received conservative surgery, removal of
only the necrotic bone and extensive surgery, defined
as removal of the necrotic and surrounding bone











Radical surgical excision of all diseased bone and
nasio-labial flap reconstruction. Complete healing 6 months




Hemimandibulectomy and an osteocutaneous fibula
flap reconstruction Complete healing 24 months




Segmental resection and immediate reconstruction
with a reconstruction plate were performed.
3/4 patients
completely healed 12 months




Large necrotic bone segment was removed by an
ultrasonic bone saw. A bone file or rongeur was used
for rounding the sharp bone edge. Then, the bone
defect was closed by sutures or COE pack.






Segmental mandibulectomy and microvascular free
flap reconstruction. Complete healing
Average of 15
months







Re-sective procedures were defined as corticotomy,
surgical removal of the lesion and extended bone
removal without prejudice for the continuity of the
mandible/maxilla.
68% patients








Extensive surgery, defined as removal of the necrotic
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Table 3. Summary of the characteristics and the results of the studies on MRONJ surgery plus non-invasive procedures.
Study Study Type Population Intervention Outcome Follow-Up
Conservative surgery plus (+) non-invasive procedures
1. Surgery + Blood
Component




Sequestrectomy + PRF Complete resolution 18 months




Curettage + PRF Complete resolution 6 months




Resection of the necrotic tissues,
curettage and osteotomy + L-PRF Partial healing 6 months




Sequestrectomy or curettage + PRF Complete resolution 1 month




Curettage + L-PRF 93.3% patientscompletely healed 20 months












Curettage + PRP Complete resolution 14 months




Conservative surgery + PRFG Complete resolution From 48 to 50 months





sequestrectomy + PRF Complete resolution 10 months
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Table 3. Cont.
Study Study Type Population Intervention Outcome Follow-Up




Sequestrectomy and curettage +
PRF Complete resolution
An average of 20
months




Conservative surgery + L-PRF 36% patientscompletely healed 4 months
Fernando de
Almeida Barros





Surgical removal of necrotic bone +
PRF membranes Complete healing 24 months




Surgical removal of necrotic bone +
PRF membranes Complete healing 60 months
Bouland C et al., 2020 Case report
N = 2
Ost + Onc
Stage 2 and 3
Surgical removal of necrotic bone +
SVF and L-PRF membranes Complete healing 18 months
2. Surgery + Blood
Component +
Photodynamic Therapy




Surgical debridement + PDT + PRF Complete resolution An average of 12months








Conservative surgery + combined
L-PRF and recombinant human
BMP-2 (rhBMP-2)
60% patients
completely healed 4 months




Sequestrectomy + teriparatide Complete resolution 6 months
5. Surgery + Teriparatide +
Bone Morphogenetic
Protein





absorbable collagen plugs soaked
by rhBMP-2 into the bone defect
plus daily subcutaneous injection of
20 mg teriparatide for 1–4 months.
Complete resolution 3 months
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Table 3. Cont.
Study Study Type Population Intervention Outcome Follow-Up
6. Surgery + Bone





absorbable collagen plugs soaked
by rhBMP-2 into the bone defect.
Complete resolution 3 months
7. Surgery + Blood
Component + Autolugus
Bone Marrow Stem Cells
Gonzálvez-García




Removal of the necrotic bone+ bone
marrow stem cells + beta tricalcium
phosphate + demineralized bone
matrix + PRP
Complete resolution 6 months




Debridement of the exposed
necrotic bone followed by bone










GaAlAs diode laser every 48 h for
10 days + antibiotic therapy +
curettage
Complete resolution 6 months










Pre- and post-operative antibiotic
administrations + GaA-lAs diode
laser








Conservative surgery + low-level
laser therapy application (Er:YAG
and Nd:YAG)
70% patients
completely healed 12 months




Conservative surgery + laser
Nd:YAG
89% patients
















Conservative surgery + continuous
indium-gallium-aluminum-
phosphide diode laser. The LPT
treatment started on the first visit
and continued daily until mucosal
healing was observed.
86% patients
completely healed 12 months
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Table 3. Cont.
Study Study Type Population Intervention Outcome Follow-Up




Curettage or sequestrectomy +
Ozone therapy (3 min sessions
2/week) + pharmacological therapy
90% patients
completely healed
An average of 6
months







pre-operative HBO therapy for 20
sessions, conservative minor
surgical debridement and again










surgery (debridement of bone
sequestra) and daily rinsing with
chlorhexidine mouthwash.
Complete resolution 12 months




40 HBO treatments at 2.0 atm for 2 h
twice per day and conservative
surgical debridement of the necrotic
bone.
52% patients
completely healed 24 months
12. Ozone + Surgery*




Antibiotic + antimycotic therapy for
10 days. Local ozone gas (total of 15
applications). Conservative surgery
(sequestrectomy).
Complete resolution 36 months




Weekly irrigation with aqueous
ozone solution on bone-exposed
region + daily mouthwashes of
ozone solution. After 3 and 6
months: conservative surgery
(debridement and sequestrectomy)
Complete resolution An average of 24months
Int. J. Environ. Res. Public Health 2021, 18, 8432 11 of 23
Table 3. Cont.
Study Study Type Population Intervention Outcome Follow-Up
13. Teriparatide + Surgery *




After 4 months of daily teriparatide
therapy conservative surgery
(sequestrectomy). The TPTD
therapy was terminated 6 months
after the initial treatment.
Complete resolution 20 months




Daily Teriparatide (20 µg/day) 1–3
months + conservative sequestrec-
tomy/marginal/aggressive
segmental resection
Complete resolution 3 months




Daily teriparatide (20 µg/day)
ranged from 4 to 24 months. In
some cases, surgery was performed
to obtain the healing.
Partial resolution





Aggressive surgery plus non-invasive procedures








Partial mandibulectomy + bone
graft from the iliac crest + rhBMP-7 Complete resolution 60 months







Osteotomy with Er:YAG laser + AF
visualization to guide the
osteoplasty. Intraoral irrigations
with povidone iodine solution +
application of Nd:YAG laser +
weekly applications of LLLT for 3
weeks after intervention
Complete resolution 7 months
* Procedures administered prior to surgery.
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2.2.2. Data Collection Process
Data collection was independently performed by two authors (F.C. and A.G.), and
their results were reviewed by a third author (O.D.F.) to check for accuracy.
2.2.3. Statistical Analysis
Selected studies were reviewed to detect outcomes of interest. A standard extraction
template was used to collect raw data. The extracted data comprised the sample size (n),
and treatment and clinical outcomes, including: (a) a 6-month complete resolution rate,
or (b) a 6-month improvement (in terms of a transition from a higher to a lower stage)
rate. Some results were not present in all the trials included in the review. The pooled
results for each of the four categories were based on weighted estimates. The I2 statistic
test was conducted in order to assess heterogeneity among the included studies. If an
I-squared value was lower than 50%, the fixed-effect-based Mantel–Haenszel model was
used in order to present variables as weighted measures; if it was higher than 50%, the
pooled analysis was performed using the random effect-based model by Der Simonian and
Laird. The overall (a) and (b) rates were reported as pooled proportions of the percentage
of patients who had been treated with one of the four experimental categories. A two-
tailed Student’s t-test with a significance level of 0.05 was used for all comparisons. All
analyses were performed using the 15.0 MedCalc for Windows version (MedCalc Software,
Ostend, Belgium).
3. Results
The initial search strategy identified 371 records, which were obtained by database
searching, after the duplicates had been removed. Two reviewers (F.C. and A.G.) indepen-
dently screened the titles and abstracts to arrive at a total of 121 articles, and 62 duplicates
were excluded. Of the 83 articles, 30 did not meet the inclusion criteria for this review,
thus 53 articles were eligible (Figure 1). Forty-one out of the fifty-three articles reported
only one procedure, and twelve described more than one treatment. Only data from the
four relevant categories were extrapolated and included in the pooled analysis. Thus,
some studies have been replicated in the distribution among the four categories, taking
into account that several authors described different procedures. Authors classified and
staged MRONJ cases in all articles in accordance with the guidelines of the American
Association of Oral and Maxillofacial Surgeons [27,28]; however, data regarding the extent
of the disease was not always available.
Conservative surgery alone: 19 articles were included in this analysis. Even where
different surgical approaches had been described, conservative surgery was always pre-
ceded by medical treatment (antiseptic mouthwash and systemic antibiotics). Nine out of
the nineteen articles were case reports or case series, with a positive outcome in 100% of
the treated patients (N = 52, cancer and osteoporotic patients), with a follow-up period of
nearly twelve months. Of the remaining 10 articles (N = 375, stages 1, 2, 3 cancer and osteo-
porotic patients), the overall outcome was successful in the vast majority of cases, recording
high success rates of 70% on average with a follow-up period of 9 months (Table 2).
Aggressive surgery alone: 7 articles were included in this analysis. Similarly, the
practice of aggressive surgery was always preceded by medical treatment (antiseptic
mouthwash and systemic antibiotics). Four of the seven articles were case reports or case
series with positive outcomes in 100% of treated patients (N = 25, cancer and osteoporotic
patients), with a follow-up period of nearly twelve months. In the 3 remaining articles
(N = 245 cancer and osteoporotic patients), the overall outcome was successful in the vast
majority of cases, recording high success rates of 70% on average with a follow-up period
of 12 months (Table 2).
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a positive outcome in 100% of treated patients (N = 51, cancer and osteoporotic patients), 
with a follow-up period of nearly 11 months. In 15 articles (N = 348, cancer and osteopo-
Figure 1. A PRISMA flow chart of the pooled studies.
Conservative surgery plus non-invasive protocol (auxiliary treatment): 36 articles
were included in this an lysis, 22 of which w re ase reports or case series (<10 pts) with
a positive outcome in 100% of treated patients (N = 51, cancer and osteoporotic patients),
with a follow-up period of early 11 months. In 15 articles (N = 348, cancer and oste porotic
patients), the o rall outcome was successful in almo t all cases, recording high success
rates of 80% on average with a follow-up period of 8 months. All 36 articles were divided
into 13 subc teg ries on the basis of differ nt auxi iary treatments [29–59].
Aggres ive surgery plus non-invasive procedures (auxiliary treatment): only two
papers (ca e reports) discussed the results of aggressive surgery protocols with auxiliary
treatment [49,60].
Table 3 provides a comprehensive overview of these findings of the last categories.
Considering that only studies with n > 10 patients were reviewed for the final pooled
analysis, a total of 1137 patients were included in the study and assigned to one of the
four categories according to their specific intervention. No significant differences between
median age and sex were reported as the result of a comparison of the four groups.
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The overall 6-month total resolution rate (a) and the 6-month improvement rate (b)
were: 74% (CI 95%; 64–83%) and 87% (CI 95%; 78–94%), respectively. The following was
reported for (a):
• 80% (CI 95%; 68–90%) for invasive surgery alone (Figure 2a).
• 69% (95% CI; 53–84%) for invasive surgery plus non-invasive procedures (Figure 2b).
The following was reported for (b):
• 81% (CI 95%; 67–92%) for invasive surgery alone (Figure 3a).
• 92% (CI 95%; 88–94%) for invasive surgery plus non-invasive procedures (Figure 3b).
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and (b) invasive (conservative/aggressive) plus non-invasive treatments.
Stratifying for each category of invasive procedures with respect to (a) and to (b), the
data are collated in Table 4.
Of interest, a significant statistical difference was observed in the 6-month improve-
ment rate, on comparing combined conservative surgery (mean = 91%) versus only surgical
(conservative alone and aggressive alone) techniques (mean 77%, p = 0.05). There was no
significant difference for any group with respect to the 6-month total resolution rate (82%
versus 72%, respectively). No reliable data were available for an analysis of aggressive
surgery plus a non-invasive procedure with respect to all the selected indicators.
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Table 4. Stratification for each category of invasive procedures with respect to (a) and to (b).
6-Month Total Resolution Rate
(a) 6-Month Improvement Rate (b)
Conservative surgery alone 67% (IC 95%; 50–83%) 82% (IC 95%, 65–95%)
Aggressive surgery alone 93% (IC 95%; 82–99%) 72% (IC 95%; 64–80%)
Conservative surgery plus non-invasive procedures 75% (IC 95%; 60–87%) 91% (IC95%; 87–96%)
Aggressive plus non-invasive procedures not assessable not assessable
4. Discussion
The most profound effect of MRONJ in patients is the crippling nature of this disease
with its negative impact on the quality of life. Thus, the challenge of the medical practitioner
in treating these patients is undoubtedly to select the most appropriate medical protocols
for maximizing a positive outcome for the patient.
Generally, the management of patients who are unable to achieve restitutio ad integrum
(total recovery) will imply that the physician accompanies their patients on a journey of
chronic illness. However, this may also include the pursuance of innovative research in
adhering to appropriate protocols. Nowadays, it is possible for the symptoms of MRONJ
to regress to a considerable degree or for the disease to partially heal in the absence of signs
of phlogosis and demarcation of the necrotic process. All these features of healing can be
considered as the primary goals for MRONJ management [61].
Unfortunately, there currently lacks consensus regarding the most appropriate treat-
ment strategy for MRONJ. This may, in part, be due to the heterogeneity of MRONJ
staging and available treatments; indeed, the majority of proposed protocols are surgical
(conservative or aggressive). A conservative surgical approach can be deployed with the
debridement of the superficial necrotic bone or by sequestrectomy, in addition to the use of
systemic antibiotics and local antiseptic products [62–69]. An aggressive surgical approach
will be adopted when conservative debridement has failed; in advanced cases of MRONJ, it
is characterized by the partial or total resecting of the necrotic/non-necrotic tissue [70–72].
Two parameters, which are considered fundamental in deciding how to treat MRONJ,
are staging and healing. A well-established staging system should be used to quantify the
severity and extent of MRONJ and to guide decision-making [73]. Nowadays, AAOMS
staging, as it is often termed, does not always satisfy the requisites for MRONJ treatment
since it does not take into account the effective anatomical/radiological extent of the dis-
ease [28]. In this regard, Campisi et al. have recently highlighted this limitation, concluding
that it may not always be effective and appropriate to propose MRONJ treatments based
on the staging system [74]. The trials relating to their research, included in this systematic
review, do not contain data stratified by disease stage, thereby precluding a pooled evalua-
tion on this key topic. With the aim of facilitating reading, the authors of this paper have
inserted the staging system used in every case series in order to complete the descriptive
data (Tables 1 and 2). Of note, the choice of a given surgical protocol in some cases was
found to be independent of the staging evaluation.
Healing is another pillar of MRONJ management. Based on an assessment of symp-
tomatology, and clinical mucosal and radiological signs, specific terms have recently been
proposed to improve the descriptions of treatment outcomes. Examples include: “re-
solved”, “improving”, “stable” and “progressive” [73]. Unfortunately, most academic
papers have described the process of healing by merely referring to the integrity of mucosa
as being seamless and symptomless, however without evaluating the underlying bone,
from which the disease develops and recurs [75]. Furthermore, follow-up periods are
often very short (approximately 6 months), and they exclude a recurrence at 6–12 months
after the surgical procedure [6,76]. The analysis proposed herein has described healing as
complete or partial as the authors have limited their descriptions to using undefined data.
Referring to the main results of this systematic analysis, high success rates (70% on
average) with a follow-up period of 9 months were recorded in almost all treated patients
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(N = 375) who had been treated solely according to a conservative surgical approach.
Approximately 70% of the 270 MRONJ patients, who had been treated solely with ag-
gressive surgery and a follow-up of more than 12 months, also had a successful MRONJ
outcome. Of this latter group, aggressive surgery alone was deployed in stage 1 of the
disease [23,65,77]. This surgical choice is not supported by statements or guidelines, but it
is left to the discretion of the surgeon; it does not, therefore, permit a reliable analysis of
the results.
In a dissimilar manner, a non-invasive procedure (auxiliary therapy) was combined
with conservative surgery, whilst there are fewer cases of aggressive surgery reported
in the literature. When conservative surgery was combined with auxiliary therapy in
the management of 401 patients, the optimum patient outcome was achieved by only
considering the data of partial healing, and no differences have been reported in the
literature when complete resolution (healing) was evaluated (Figures 2 and 3).
Auxiliary therapy consists of several agents with antiseptic, angiogenic and biomod-
ulatory properties. Of these, platelet-rich fibrin (PRF) is a second-generation platelet
concentrate. PRF membranes appear to be an easy and cheap alternative treatment with
which to close exposed bone in MRONJ after surgical treatment [78–81]. They promote
gingival healing by acting as a barrier membrane between the alveolar bone and the oral
cavity, thereby accelerating physiologic wound healing and new bone formation. This min-
imizes recurrent infections and it prevents osteonecrotic lesions [34–36,38,50,82]. Moreover,
leukocyte and platelet-rich fibrin (L-PRF and PRF, respectively) are determinant in immune
regulation, which may be of importance in reducing tissue infection in the immediate
postoperative period [83–85]. The association between surgery and blood components
(such as platelet-rich—PRP or PRF or L-PRF) in the analysis presented in this paper has
proved itself to be an effective treatment for the rapid closure of bone exposure and the
formation of new gingival tissue in the absence of signs of phlogosis. With a success rate of
95%, several authors have demonstrated that this association is effective on average over a
14-month follow-up period.
Another safe and effective treatment has also been described in the literature: PRF and
PRP have been associated with laser phototherapy by virtue of the elevated microbicidal
activity of the laser [16,43], making use of autologous bone marrow stem cells. This research
has reported effective results by virtue of the osteogenic and chondrogenic potential of these
agents (PRF and PRP), in addition to their capacity for vasculogenesis and angiogenesis [43].
De Santis et al [86] described two case reports treated with the debridement of the exposed
necrotic bone followed by bone marrow stem cells injection: a positive follow up with no
sing or symptoms in the necrotic area has been reported for the next 13 months.
Referring to the systematic review described herein, the associations between con-
servative surgery plus blood components, and laser or photodynamic therapy, appear to
contribute much to: newly formed bone, the full coverage of bone tissue with healthy
mucosa and the absence of symptoms and other signs of necrotic progression. This is due
to the analgesic, anti-inflammatory and biomodulatory effects of blood components, and
this protocol has been shown to be effective on average over a 6-month follow-up period
with a success rate of 86%.
The association of autologous bone marrow stem cells with conservative surgery and
blood components has been reported only in one case study, with a success rate of 100%
on average over a 6-month follow-up period. The CT scan revealed the diminution of
osteolytic lesions with complete bone regeneration of the medial cortex of the lower jaw
and a total resolution of symptoms.
An early resolution of MRONJ has been reported when combining conservative
surgery and the use of bone morphogenetic protein (BMP-2) or SVC (stromal vascular
fraction: a heterogeneous cell population containing mesenchymal stromal cells isolated
by adipose tissue) and L-PRF: the addition of BMP to L-PRF stimulates soft tissue healing
and bone remodeling, thereby promoting total mucosal coverage in the absence of signs of
phlogosis and exposed bone, leading to a marked diminution of symptoms. Thus, patients
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requiring the continued administration of antiresorptive treatment may benefit from such
a combined regimen [31,87].
Moving on to another study, Jung et al. [42] have proposed a concomitant adminis-
tering of BMP-2 with teriparatide (TPTD) in order to maximize the regeneration of bone
after surgery. In a synergistic manner, TPTD stimulates an anabolic effect by accelerating
the osteoblastic differentiation of the BMP [88]. This result may prompt a paradigm shift
in the treatment of MRONJ from resecting to regeneration. The association between BMP
and TPTD had a success rate of 100% over a 3-month follow-up period. The addition of
TPTD to BMP enhances remodeling and the formation of bone, thereby facilitating healing
and the removal of necrotic bone. Many patients experience a complete resolution of their
symptoms with no signs of phlogosis.
Low-level laser therapy (LLLT) has been used in treating MRONJ patients, together
with an AF-guided surgical or a conventional surgical approach. It is considered by many
as a safe and effective adjunct to the medical-surgical treatment of MRONJ lesions because
it stimulates the regeneration and angiogenesis of soft tissues, thereby increasing the
duration of the healing process. However, there still exists controversy regarding the
physical and biological variables of LLLT, including: the type of laser, the frequency of the
light pulse, output power, duration of application, fluence, and the distance of the source
from the irradiated tissue [45–49]. The association of LLLT with surgery has demonstrated
a success rate of 87% on average over a 12-month follow-up period, with total mucosal
healing in the absence of signs of infection or pain.
The use of surgery has also been associated with teriparatide (TPTD) treatment (prior
to or after conventional surgical treatment) for MRONJ in osteoporotic patients. TPTD
stimulates trabecular and cortical thickness, and trabecular connectivity and bone size bone
formation by increasing osteoblast number and activity. Although successful results using
TPTD treatment have been reported in the literature, its safety and efficacy are currently
awaiting comprehensive evaluation. The treatment time during which it can be safely
administered is strictly limited to less than 2 years in one lifespan [57–59]. A success rate
of 83% on average over an 11-month follow-up period has been reported for the surgical
treatment plus TPTD treatment (or vice versa) of MRONJ: any surgical wound completely
healed with X-rays indicating stable alveolar bone. No inflammatory signs and symptoms
have been reported to date.
Other protocols (for example, the use of ozone and hyperbaric oxygen (HBO)) have
also been deployed and evaluated as a MRONJ surgical adjuvant treatment. Ozone has been
used with different formulations (i.e., an oral irrigation of aqueous ozone, gas insufflation)
and duration (prior to or after surgical curettage or sequestrectomy) by virtue of its positive
features. These include: antimicrobial power, an enhancement of tissue oxygenation, an
activation of the immune response, a stimulation of angiogenesis and fibroblast formation
and analgesic agents [51,55,56,89]. In this review, the association between ozone and
conservative surgery (or vice versa) demonstrated a success rate of 90–100% on average
over a 22-month follow-up period. Complete mucosa healing was seen in the absence of
symptoms such as pain and local inflammation.
As a pre-surgical treatment, HBO has successfully treated MRONJ lesions, thereby:
improving the quality of life of afflicted patients [52–54], increasing wound healing, and
reducing edema, inflammation and pain. HBO followed by surgical treatment had a success
rate of 84% on average over an 18-month follow-up period, with: the complete healing of
MRONJ lesion, total mucosal coverage, a cessation in the signs of infection and notable
symptomatic relief.
5. Conclusions
The authors of this paper performed an evidence-based analysis which demonstrated
the compelling and effective performance of non-invasive procedures, combined with
conservative and aggressive surgery, in treating MRONJ patients. The data confirmed that
partial and complete 6-month resolution rates ranged from 70% to 100%. Of note, adjuvant
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therapy usually requires daily or weekly applications. Such a regular clinical practice
permits the surgeon to constantly monitor the MRONJ lesion and to promptly modify
treatment, where indicated. It is also hoped that many patients will be more inclined
to maintain effective oral hygiene on account of their continual checkups. Moreover, an
alleviation in symptoms has been achieved using appropriate treatments within a relatively
short period of time and in the absence of negative events.
Many MRONJ patients can achieve total remission by means of aggressive surgical
treatment, which is similar in mean duration to conservative surgery alone (9–12 months).
This is notwithstanding other considerations, such as the patient suffering from a debil-
itating disease, the exacerbation of the quality of life with marked morbidity and, last
but not least, challenging conditions for patients after aggressive surgery. These factors
must be taken into account if patients also suffer from a significant systemic disease (e.g.,
metastatic patients) [41]. It might be opportune to highlight in cancer patients the appropri-
ate choice of an MRONJ management protocol by conservative surgery with the addition of
ozone [51], LLLT [45] or blood component + Nd:YAG [47] laser treatment. The analysis in
this paper has demonstrated improved results in treating MRONJ with nearly total healing.
Regrettably, there is a lack of reported data relating to the use of aggressive surgery plus
auxiliary protocols, which would have been included in the pooled analysis.
Finally, some studies discussed in this paper confirmed an extended follow-up period
for patients. This represents a key point in evaluating the healing of MRONJ, as has been
previously highlighted by two Italian scientific bodies of oral pathology and medicine, and
maxillofacial surgery: SIPMO and SICMF, respectively [74]. Their research has defined
clinical and radiological MRONJ healing with a documented absence of symptoms and the
clinical signs of MRONJ in a period of no less than 12 months [1,3,90].
Despite the systematic nature of the analysis in this paper, there are limitations relating
to: the non-randomized retrospective/prospective nature of the studies herein, the analysis
of historical data, the heterogeneity of patients included in the study and a suitable defi-
nition of the endpoints being examined (the complete and partial resolutions of MRONJ
symptoms).
To the best of our knowledge, the following regarding MRONJ treatment can be
highlighted:
(1) A unanimous factual definition, including evaluation criteria (diagnosis and stag-
ing), is fundamental in assessing the efficacy of well-specified MRONJ treatment in order
to facilitate a systematic analysis of the results of the research.
(2) The main positive outcomes of MRONJ treatment should be: the absence of
symptoms, clinically active phlogosis and the obstacle of the relevant area of bone, as
recognized on CT scans for a period of at least 12 months.
(3) Many in the field would say that the treatment of MRONJ is unquestionably related
to its staging and the systemic status of the patient: cancer patients have often the worst
quality of life, and aggressive surgery can exacerbate their condition.
(4) Conservative surgery combined with adjuvant procedures (i.e., ozone, LLLT or
blood component + Nd:YAG laser treatment) can contribute to partial or total healing in
all stages of MRONJ, with improved results and variables (from symptoms to clinical and
radiological signs).
(5) Adjuvant therapy associated with surgery (conservative or aggressive) may be the
future for MRONJ treatment. This combination could lead to the most positive results, but
it is also of the utmost importance for conducting further effectively controlled studies in
order to arrive at conclusive statements for the effective treatment of MRONJ.
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